Cargando…
Additive antiangiogenesis effect of ginsenoside Rg3 with low-dose metronomic temozolomide on rat glioma cells both in vivo and in vitro
BACKGROUND: Glioblastoma is the most common and deadly primary brain tumor in adults. Low-dose,metronomic (LDM) temozolomide (TMZ) displays improved efficacy in the treatment of glioblastoma by targeting angiogenesis, but has a limited effect on recurrence. The antiangiogenesis drug ginsenoside Rg3...
Autores principales: | Sun, Caixing, Yu, Yang, Wang, Lizhen, Wu, Bin, Xia, Liang, Feng, Fang, Ling, Zhiqiang, Wang, Shihua |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4752767/ https://www.ncbi.nlm.nih.gov/pubmed/26872471 http://dx.doi.org/10.1186/s13046-015-0274-y |
Ejemplares similares
-
Phase I study of low-dose metronomic temozolomide for recurrent malignant gliomas
por: Wong, Eric T., et al.
Publicado: (2016) -
Isthmin inhibits glioma growth through antiangiogenesis in vivo
por: Yuan, Bangqing, et al.
Publicado: (2012) -
Metronomic Doses of Temozolomide Enhance the Efficacy of Carbon Nanotube CpG Immunotherapy in an Invasive Glioma Model
por: Ouyang, Mao, et al.
Publicado: (2016) -
20(S)‐ginsenoside‐Rg3 reverses temozolomide resistance and restrains epithelial‐mesenchymal transition progression in glioblastoma
por: Chen, Zheng, et al.
Publicado: (2018) -
Ginsenosides Rg1 and CK Control Temozolomide Resistance in Glioblastoma Cells by Modulating Cholesterol Efflux and Lipid Raft Distribution
por: Qiu, Runze, et al.
Publicado: (2022)